Quark Begins Dosing Second Patient Subgroup in Phase I Study of Ocular Neuroprotection siRNA Drug

The Phase I study is being conducted in the US and Israel with two patient subgroups — stratum I, which includes patients with chronic nerve atrophy and began dosing in March; and stratum II, which is enrolling patients with recent onset of NAION.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.